M
Marco Daperno
Researcher at University of Turin
Publications - 152
Citations - 6867
Marco Daperno is an academic researcher from University of Turin. The author has contributed to research in topics: Inflammatory bowel disease & Ulcerative colitis. The author has an hindex of 32, co-authored 120 publications receiving 5650 citations.
Papers
More filters
Journal ArticleDOI
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollón,Axel Dignass,Vito Annese,Herbert Tilg,Gert Van Assche,James O. Lindsay,Laurent Peyrin-Biroulet,Garret Cullen,Marco Daperno,Torsten Kucharzik,Florian Rieder,Sven Almer,Alessandro Armuzzi,Marcus Harbord,Jost Langhorst,Miquel Sans,Yehuda Chowers,Gionata Fiorino,Pascal Juillerat,Gerassimos J. Mantzaris,Fernando Rizzello,Stephan R. Vavricka,Paolo Gionchetti +22 more
TL;DR: The methodology of the consensus process, and the classification, diagnosis and medical management of active and quiescent Crohn’s disease of this ECCO Consensus are concerns.
Journal ArticleDOI
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD
Marco Daperno,Geert D'Haens,Gert Van Assche,Filip Baert,Philippe Bulois,Vincent Maunoury,Raffaello Sostegni,Rodolfo Rocca,Angelo Pera,A.M. Gevers,Jean-Yves Mary,Jean-Frederic Colombel,Paul Rutgeerts +12 more
TL;DR: The aim of this study was to develop and to prospectively validate a simpler endoscopic score of disease activity, the Simple Endoscopic Score for Crohn's Disease, which was correlated to clinical parameters and serum C-reactive protein level.
Journal ArticleDOI
European evidence based consensus for endoscopy in inflammatory bowel disease
Vito Annese,Marco Daperno,Matthew D. Rutter,Matthew D. Rutter,Aurelien Amiot,Peter Bossuyt,James E. East,Marc Ferrante,Martin Götz,Konstantinos Katsanos,Ralf Kießlich,Ingrid Ordás,Alessandro Repici,Bruno Rosa,Shaji Sebastian,Torsten Kucharzik,Rami Eliakim +16 more
TL;DR: The development of guidelines is an expensive and time-consuming process, but this Consensus may help to avoid duplication of effort in the future and identify issues where the evidence is lacking and controlled studies are awaited.
Journal ArticleDOI
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.
Mario Cottone,Anna Kohn,Marco Daperno,Alessandro Armuzzi,Luisa Guidi,Renata D'Incà,Fabrizio Bossa,Erika Angelucci,Livia Biancone,Paolo Gionchetti,Sandro Ardizzone,Claudio Papi,Walter Fries,Silvio Danese,Gabriele Riegler,Maria Cappello,Fabiana Castiglione,Vito Annese,Ambrogio Orlando +18 more
TL;DR: Patients older than 65 years treated with TNF inhibitors for IBD have a high rate of severe infections and mortality compared with younger patients or patients of the same age that did not receive these therapeutics.
Journal ArticleDOI
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study.
Cristina Bezzio,Simone Saibeni,Angela Variola,Mariangela Allocca,Alessandro Massari,Viviana Gerardi,V. Casini,Chiara Ricci,Fabiana Zingone,Arnaldo Amato,Flavio Caprioli,Marco Vincenzo Lenti,Chiara Viganò,Marta Ascolani,Fabrizio Bossa,Fabiana Castiglione,Claudio Camillo Cortelezzi,Laurino Grossi,Monica Milla,D. Morganti,Luca Pastorelli,Davide Giuseppe Ribaldone,Alessandro Sartini,Alessandra Soriano,Gianpiero Manes,Silvio Danese,M.C. Fantini,Alessandro Armuzzi,Marco Daperno,Gionata Fiorino +29 more
TL;DR: Active IBD, old age and comorbidities were associated with a negative COVID-19 outcome, whereas IBD treatments were not, and Preventing acute IBD flares may avoid fatal CO VID-19 in patients with IBD.